Clinical Research Papers:
Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy
Metrics: PDF 903 views | HTML 1498 views | ?
In Rae Cho1,2, Hye Won Lee1,2, Ki Jun Song2,4, Beom Kyung Kim1,2,3, Seung Up Kim1,2,3, Do Young Kim1,2,3, Sang Hoon Ahn1,2,3, Jinsil Seong2,5, Kwang-Hyub Han1,2,3 and Jun Yong Park1,2,3
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2Yonsei Liver Center, Severance Hospital, Seoul, Korea
3Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
4Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea
5Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
Jun Yong Park, email: firstname.lastname@example.org
Keywords: advanced hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B/C, conditional survival, hepatic arterial infusion chemotherapy, concurrent chemoradiotherapy
Received: June 12, 2017 Accepted: August 04, 2017 Published: August 18, 2017
Conditional survival (CS) provides a prognosis of patients who have already survived several years after treatment. We investigated CS in Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) with or without concurrent radiotherapy (CRT). A total of 181 patients diagnosed with HCC who were treated with HAIC with or without CRT between 2011 and 2015 were retrospectively reviewed. Overall survival (OS) and CS were calculated and a subgroup analysis was performed. The 1- and 5-year survival rates of all patients were 57.0% and 24.3%. OS was significantly higher in patients with BCLC stage B than BCLC stage C patients. Patients who achieved disease control after treatment also showed longer OS than who did not respond to treatment. Provided that the patient had already survived for 0, 1, 2, and 3 years, the CS estimates of surviving an additional 2 years were 35.6%, 55.1%, 82.0%, and 77.4%, respectively. A subgroup analysis was performed to compare BCLC stage B and C patients and revealed that CS has a tendency to increase and the difference in CS between two groups decreased over time. CS reflects the change of prognosis over time and may provide a more accurate prognosis and hopeful message to patients who have already survived with treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.